ResearchOpen Access19 May 2025Nature Communications Volume: 16, P: 4638 Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes Wilkerson et al. interrogate transcriptomic and proteomic peripheral immune signatures that associate with response to ...
Nature Reviews Genetics thanks M. K. Levings, Z. Li, E. L. Smith, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliati...
As an antitumour vaccine, the microbial platform must also facilitate presentation of recombinant antigens and activation of APCs. To evaluate the system in this capacity, the model antigen ovalbumin (OVA) was expressed in the cytosol of EcNcΔlon/ΔompTusing a strategy analogous to that used f...
1976; Cancer Immun 1:6, 2001). Since then, the last century’s dream has been to effectively prevent and cure cancers by immunological means. This dream
This review introduces all aspects of immunotherapy in detail, and analyzes the literature related to tumor immunity to reveals the mysterious veil of immunotherapy. 2. Cellular immunotherapy for tumors Immune cells can identify and kill tumors. By stimulating immune cells and using the body's own ...
[25,26]. In this review, we will summarize which advances in immunotherapy may translate into improved PDAC treatment options. In addition, we will discuss which combinatorial approaches are likely to maximize the potential of immunotherapy and, thus, may serve as light at the end of the ...
Considering that ICEs are a rapidly expanding biotechnology in cancer therapy, we designed this review as a primer for clinicians, focusing on the major obstacles for the clinical implementation and the most translatable approaches proposed to overcome the limitations in solid tumors....
Kirtane K, Elmariah H, Chung CH, Abate-Daga D.Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.J Immunother Cancer. 2021;9(7):e002723. doi:10.1136/jitc-2021-002723. Sterner RC, Sterner RM.CAR-T cell therapy: current limitations and potent...
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2022;11(2):277-294. doi:10.21037/tlcr-22-75 PubMedGoogle ScholarCrossref 13. Ge S, Huang C. Immune checkpoint inhibitors in neoadjuvant...
In the current review, we summarized recent advances regarding the role and underlying mechanisms of B cells in human cancer and therapy. Some studies have shown that B-cell abundance in cancer is positively associated with favourable clinical outcomes, while others have indicated that they are ...